RhumbLine Advisers
EIGR

RhumbLine Advisers’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

RhumbLine Advisers’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77
Closed -$522 – 4273
2023
Q4 		$522 Hold
77
– – ﹤0.01% 4199
2023
Q3 		$707 Sell
77
-86
-53% -$1.73K ﹤0.01% 4210
2023
Q2 		$3.44K Sell
163
-1,686
-91% -$51.9K ﹤0.01% 4142
2023
Q1 		$50K Buy
1,849
+49
+3% +$2.28K ﹤0.01% 2908
2022
Q4 		$64K Sell
1,800
-12
-0.7% -$1.44K ﹤0.01% 2936
2022
Q3 		$409K Buy
1,812
+111
+7% +$27.3K ﹤0.01% 2590
2022
Q2 		$321K Buy
1,701
+430
+34% +$86.7K ﹤0.01% 2718
2022
Q1 		$316K Sell
1,271
-26
-2% -$4.11K ﹤0.01% 2627
2021
Q4 		$202K Sell
1,297
-21
-2% -$4.06K ﹤0.01% 2833
2021
Q3 		$264K Buy
1,318
+36
+3% +$8.56K ﹤0.01% 2819
2021
Q2 		$328K Buy
1,282
+399
+45% +$99.6K ﹤0.01% 2755
2021
Q1 		$234K Sell
883
-53
-6% -$16.7K ﹤0.01% 2787
2020
Q4 		$345K Buy
936
+115
+14% +$33K ﹤0.01% 2610
2020
Q3 		$201K Sell
821
-94
-10% -$29.2K ﹤0.01% 2688
2020
Q2 		$263K Buy
915
+174
+23% +$51.3K ﹤0.01% 2640
2020
Q1 		$151K Sell
741
-19
-3% -$6.06K ﹤0.01% 2673
2019
Q4 		$340K Buy
760
+41
+6% +$14.6K ﹤0.01% 2533
2019
Q3 		$221K Buy
719
+18
+3% +$5.85K ﹤0.01% 2715
2019
Q2 		$223K Buy
+701
New +$243K ﹤0.01% 2747

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

RhumbLine Advisers's EIGR Position: Q1 2024 in Review

RhumbLine Advisers sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 77 shares — an estimated $522 sold.

RhumbLine Advisers first reported a position in EIGR in Q2 2019 and held it in 19 quarters. The position peaked at $409K in Q3 2022. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • RhumbLine Advisers reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 77 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $522.
  • RhumbLine Advisers first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 19 quarters.
  • RhumbLine Advisers's Eiger BioPharmaceuticals, Inc. position peaked at $409K in Q3 2022.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.